We are live on ! Find out more
EIDX

Eidos Therapeutics, Inc. Common Stock
EIDX

Delisted

EIDX was delisted on the 25th of January, 2021.

Back to rankings

102 hedge funds and large institutions have $693M invested in Eidos Therapeutics, Inc. Common Stock in 2019 Q4 according to their latest regulatory filings, with 33 funds opening new positions, 30 increasing their positions, 27 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

230% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 10

190% more call options, than puts

Call options by funds: $16.5M | Put options by funds: $5.7M

69% more capital invested

Capital invested by funds: $411M → $693M (+$282M)

29% more funds holding

Funds holding: 79 → 102 (+23)

11% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 27

0% more funds holding in top 10

Funds holding in top 10: 5 → 5 (0)

Holders
102
Holders Change
+23
Holders Change %
+29.11%
% of All Funds
2.01%
Holding in Top 10
5
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.1%
New
33
Increased
30
Reduced
27
Closed
10
Calls
$16.5M
Puts
$5.7M
Net Calls
+$10.8M
Net Calls Change
+$10.7M

Top Buyers

Rank Fund Capital Flow
1
GGHC
Gilder Gagnon Howe & Co
New York
+$18.3M
2
Artisan Partners
Artisan Partners
Wisconsin
+$16.8M
3
DCM
Driehaus Capital Management
Illinois
+$10.8M
4
Holocene Advisors
Holocene Advisors
New York
+$8.3M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$3.76M

Top Sellers

Rank Fund Capital Flow
1
RG
Redmile Group
California
-$11M
2
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
-$8.14M
3
OAC
OMERS Administration Corp
Ontario, Canada
-$5.11M
4
Victory Capital Management
Victory Capital Management
Texas
-$4.66M
5
PHS
PFM Health Sciences
California
-$4.54M
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of New York Mellon
26
Bank of New York Mellon
New York
$3.17M +$592K +11,957 +28%
N
27
Nuveen
North Carolina
$3.16M -$128K -2,593 -4%
Goldman Sachs
28
Goldman Sachs
New York
$2.93M +$713K +14,404 +39%
EI
29
EAM Investors
California
$2.79M +$780K +15,760 +48%
CAC
30
Cowen and Company
New York
$2.69M +$2.32M +46,949 New
Charles Schwab
31
Charles Schwab
California
$2.67M +$157K +3,180 +7%
Fiera Capital (Canada)
32
Fiera Capital (Canada)
Quebec, Canada
$2.53M -$1.59M -32,042 -42%
Morgan Stanley
33
Morgan Stanley
New York
$2.11M +$1.09M +22,022 +149%
EGI
34
EAM Global Investors
California
$1.93M -$438K -8,839 -21%
RCMNY
35
Rubric Capital Management (New York)
New York
$1.64M +$1.42M +28,579 New
SEI Investments
36
SEI Investments
Pennsylvania
$1.62M +$1.4M +28,301 New
CS
37
Credit Suisse
Switzerland
$1.54M +$430K +8,683 +48%
Barclays
38
Barclays
United Kingdom
$1.51M -$281K -5,671 -18%
State of Wisconsin Investment Board
39
State of Wisconsin Investment Board
Wisconsin
$1.36M – – –
California Public Employees Retirement System
40
California Public Employees Retirement System
California
$1.33M +$40K +807 +4%
SSA
41
Schonfeld Strategic Advisors
New York
$1.25M -$3.8M -76,800 -78%
TCM
42
Tekla Capital Management
Massachusetts
$1.15M +$990K +20,000 New
Allianz Asset Management
43
Allianz Asset Management
Germany
$1.07M +$923K +18,641 New
PPA
44
Parametric Portfolio Associates
Washington
$1.06M +$915K +18,479 New
SG Americas Securities
45
SG Americas Securities
New York
$1M -$1.13M -22,848 -57%
RhumbLine Advisers
46
RhumbLine Advisers
Massachusetts
$998K +$36.1K +729 +4%
California State Teachers Retirement System (CalSTRS)
47
California State Teachers Retirement System (CalSTRS)
California
$990K – – –
AllianceBernstein
48
AllianceBernstein
Tennessee
$958K -$34.7K -700 -4%
Citigroup
49
Citigroup
New York
$900K +$687K +13,880 +767%
AQR Capital Management
50
AQR Capital Management
Connecticut
$893K +$209K +4,217 +37%
1
2
3 4 5

EIDX Hedge Fund Activity: Q4 2019 in Review

102 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Eidos Therapeutics, Inc. Common Stock (EIDX) for Q4 2019, worth a combined $693M — up 69% from $411M a quarter earlier.

Buyers outnumbered sellers: 33 funds opened new EIDX positions and 10 closed out — a net gain of 23 holders — while 30 added to existing stakes and 27 trimmed.

The largest buyer was Gilder Gagnon Howe & Co, opening a new position worth an estimated $18.3M. The largest seller was Redmile Group, cutting an estimated $11M.

  • 102 institutional investors held Eidos Therapeutics, Inc. Common Stock (EIDX) as of Q4 2019, up from 79 in Q3 2019.
  • Funds reported $693M of Eidos Therapeutics, Inc. Common Stock stock for Q4 2019, up 69% quarter-over-quarter.
  • 33 funds opened new Eidos Therapeutics, Inc. Common Stock positions in Q4 2019 and 10 closed out, a net change of +23 holders.
  • The largest Eidos Therapeutics, Inc. Common Stock buyer in Q4 2019 was Gilder Gagnon Howe & Co, an estimated $18.3M added.
  • The largest Eidos Therapeutics, Inc. Common Stock seller in Q4 2019 was Redmile Group, an estimated $11M sold.

Based on aggregated 13F filings for Q4 2019.